Drugs / Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Cell therapy targets CD19 via depletion
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02153580 | Sep 2014 → Sep 2026 expected | B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, B-cell prolymphocytic leukemia, Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma +7 | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02153580 ↗ |
| Action | Deplete | “kill cancer cells” NCT02153580 ↗ |
| Modality | Cell therapy | “cellular immunotherapy” NCT02153580 ↗ |
| Route | Intravenous | “Given IV” NCT02153580 ↗ |
| Target | CD19 | “CD19-specific” NCT02153580 ↗ |